Journal of Cataract & Refractive Surgery
Volume 35, Issue 6 , Pages 992-997, June 2009

Dissatisfaction after multifocal intraocular lens implantation

From the Emory Eye Center and Emory Vision, Atlanta, Georgia, USA

Received 15 December 2008; received in revised form 2 February 2009; accepted 3 February 2009.

Purpose

To analyze the reasons for patient dissatisfaction after phacoemulsification with multifocal intraocular lens (IOL) implantation and the outcomes after intervention.

Setting

Emory Eye Center, Atlanta, Georgia, USA.

Methods

This retrospective review comprised eyes of patients dissatisfied with visual outcomes after multifocal IOL implantation. Outcomes analyzed included type of visual complaint, treatment modality for each complaint, and degree of clinical improvement after intervention.

Results

Thirty-two patients (43 eyes) reported unwanted visual symptoms after multifocal IOL implantation, including in 28 eyes (65%) with an AcrySof ReSTOR IOL and 15 (35%) with a ReZoom IOL. Thirty patients (41 eyes) reported blurred vision, 15 (18 eyes) reported photic phenomena, and 13 (16 eyes) reported both. Causes of blurred vision included ametropia (12 eyes, 29%), dry eye syndrome (6 eyes, 15%), posterior capsule opacification (PCO) (22 eyes, 54%), and unexplained etiology (1 eye, 2%). Causes of photic phenomena included IOL decentration (2 eyes, 12%), retained lens fragment (1 eye, 6%), PCO (12 eyes, 66%), dry-eye syndrome (1 eye, 2%), and unexplained etiology (2 eyes, 11%). Photic phenomena attributed to PCO also caused blurred vision. Thirty-five eyes (81%) had improvement with conservative treatment. Five eyes (12%) did not have improvement despite treatment combinations. Three eyes (7%) required IOL exchange.

Conclusions

Complaints of blurred vision and photic phenomena after multifocal IOL implantation were effectively managed with appropriate treatment. Few eyes (7%) required IOL exchange. Neodymium:YAG capsulotomy should be delayed until it has been determined that IOL exchange will not be necessary.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Randleman is a consultant to Alcon, Allergan, and Ista. Dr. Stulting is a consultant to Alcon and Abbott Medical Optics. Dr. Woodward has no financial or proprietary interest in any material or method mentioned.

 Supported in part by Research to Prevent Blindness, Inc., New York, New York, and the National Institutes of Health Core Grant P30 EYO6360, Bethesda, Maryland, USA.

PII: S0886-3350(09)00256-9

doi:10.1016/j.jcrs.2009.01.031

Journal of Cataract & Refractive Surgery
Volume 35, Issue 6 , Pages 992-997, June 2009